Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Investor Presentation (July 2026)
46 slides from Piramal Pharma's investor presentation, July 2026
Slide 1: Investor Presentation
Investor Presentation July 2026
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Piramal Pharma - Phases of our Evolution
Piramal Pharma - Phases of our Evolution Piramal Healthcare Piramal Enterprises Ltd Piramal Pharma Ltd Domestic Formulations Pharmaceuticals Financial Services CDMO Nicholas Pharma Solutions (CDMO) CDMO Wholesale Lending Complex Hospital Generics (CHG) Laboratories Critical Care (CHG) Complex Hospit
Slide 4: Three-Pronged Business Model
Three-Pronged Business Model Contract Development and Manufacturing Organisation Complex Hospital Generics Piramal Consumer Healthcare Innovation Focused Integrated CDMO with Global Operations Critical Care Segment Consumer Health and Wellness Segment3 Inhalation Intrathecal Anesthesia Therapy North
Slide 5: Global Footprint with a Diversified Revenue Base
Global Footprint with a Diversified Revenue Base 17 100+ ~500 6,000+ ~180K PCH Customers Manufacturing and Countries with CDMO CHG Customers (Chemists and Development Sites1 Commercial Presence Customers (Hospitals) cosmetics shops) Total FY26 Revenue by Geography Total FY26 Revenue by Segments Oth
Slide 6: Global Network of Facilities – Good Blend of East and West
Global Network of Facilities – Good Blend of East and West 17 Manufacturing & Development Facilities Across North America, UK / Europe, and India 5 2 10 Grangemouth Morpeth Ahmedabad1 Pithampur Dahej Rabale Aurora Turbhe Bethlehem Digwal Lexington Mahad Sellersville Hyderabad2 Ennore Riverview API,
Slide 7: Track Record of Organic and Inorganic Expansion
Track Record of Organic and Inorganic Expansion Successfully Integrated Over 15 M&A Transactions Acquisition Business Portfolio of OTC Rationale brands from Pfizer PCH 100% stake in Convergence Little's and Expand OTC Hemmo Chemicals (Dahej Naturolax portfolio Pharmaceuticals facility) PCH CHG CDMO C
Slide 8: Track Record of Organic and Inorganic Expansion
Track Record of Organic and Inorganic Expansion Going Forward, Organic / Inorganic Investments will be Managed on the basis of Financial Performance, Debt Levels and Cash Flows Acquisitions / investments will be in line with the strategic plan, aimed at: Adding differentiated Offering synergies with o
Slide 9: Focus on Patient and Customer Centricity
Focus on Patient and Customer Centricity Focusing on Patient-centricity and Customer-centricity drives our organisation to provide flexible high-quality service while ✓ aligning us with our customer partners on our shared goal of serving patients ⚫ Customer focused integrated business ⚫ Expanding ac
Slide 10: Financial Aspirations for FY2030
Financial Aspirations for FY2030 US$ 2+ Bn Global Pharma, Health & Wellness Company by FY2030 Vision We aspire to be amongst top 10 companies in our addressable markets 3x 2x 1x Over 3x Growth in More than Double the Reduce Leverage EBITDA Revenues on the Balance Sheet ~25% US$2+ Bn ~1x EBITDA Margi
Slide 11: US$2+ Bn Company with 25% EBITDA Margin by FY2030
US$2+ Bn Company with 25% EBITDA Margin by FY2030 Strategic Goals for FY2030 US$1.2 Bn revenues with ~25% US$600 Mn revenues with 25%+ US$200 Mn revenues with double- EBITDA margin EBITDA margin digit EBITDA margin CDMO CHG PCH Emerge as a fast-growing, innovation-focused Become a leading critical c
Slide 12: Transformations to Drive Outcomes
Transformations to Drive Outcomes Transformations Outcomes Invest in Differentiated Products / Services Drive market beating CDMO: Focus on differentiated services and on-patent molecules growth with superior CHG: Shift in portfolio strategy towards speciality and differentiated products revenue mix PC
Slide 13: Accelerating Climate Action
12 Accelerating Climate Action 22.6% Reduction in Scope 1 & 2 Emissions compared to FY2022 baseline Renewable Low Carbon Energy Efficiency Energy Projects Fuel Switch & Offsets SBTi • Ennore & Dahej: Solar-wind • Digwal: Coal-fired boiler → • Site-wide energy audits 25%–42% hybrid biomass briquettes
Slide 14: Inclusion & Belonging, Human Rights, OH&S
13 Inclusion & Belonging, Human Rights, OH&S INCLUSION & BELONGING 30% Project Vardhana Employee Resource Groups ~140 women trained in STEM capabilities (4th cohort) at Digwal, driving women-led economic participation Women ERG (TrailblazHERs), Pride ERG (Riverview), Veterans ERG — building belongin
Slide 15: Experienced and Diversified Board
14 Experienced and Diversified Board Ms. Nandini Piramal Mr. Peter DeYoung Mr. Vivek Valsaraj Mr. Jairaj Purandare Mr. Sridhar Gorthi Executive Director, Executive Director, Executive Director, Non-Executive, Non-Executive, Chairperson CEO, Global Pharma Chief Financial Officer Independent Director In
Slide 16: Key Investment Highlights
15 Key Investment Highlights 1 Strong promoter group with over 35 years of demonstrated ability to build scalable and differentiated businesses 2 Presence in large multi-billion dollar size attractive industry segments with promising tailwinds 3 Globally diversified network of facilities across 3 cont
Slide 17: CDMO
6 Piramal Pharma Limited
Slide 18: Global CDMO Market
Global CDMO Market Global CDMO Market - US$ 250 Billion by 2030 Global CDMO Market1 Global CDMO Market Expected to Grow at 7-8% CAGR (In US$ Bn) Growth in global pharmaceutical market - increasing chronic and age-related disorders Rising investments in R&D to develop advanced therapeutics 240-250 Su
Slide 19: Broad Archetypes of CDMO Companies
Broad Archetypes of CDMO Companies Integrated Services Technology Specialists End-to-end offerings Value across lifecycle of Maximisers molecule (Discovery, Pharma Players Strong capability in Development, Offering CDMO specialized Commercial Services High quality and technologies manufacturing) relia
Slide 20: Service Offerings Across the Lifecycle of the Molecule
Service Offerings Across the Lifecycle of the Molecule Discovery Development Commercial Manufacturing On-Patent Off-Patent Pre-Clinical Phase I Phase II Phase III Launch Commercial Commercial Comprehensive range of Clinical development services for API and Ability to manufacture across a wide range
Slide 21: Global Manufacturing Footprint and Integrated Offerings
Global Manufacturing Footprint and Integrated Offerings Amongst Top Few CDMOs Having Network of Facilities in the West and the East (ex-China) 2 UK / Europe Facilities 5. Grangemouth 6. Morpeth 5 6 Integrated Projects 1 2 • 140+ Integrated Projects executed since 3 inception in 2020 4 • 28% contribu
Slide 22: Deep Pipeline to Fuel On-Patent Manufacturing Opportunities
Deep Pipeline to Fuel On-Patent Manufacturing Opportunities Revenue by Services Building Development Pipeline Across Clinical Phases Pre-Clinical Phase I Phase II Phase III Pre-clinical, 0.4% Others1, 16% 2% 3.0x 157 47% Phase I, 33% Innovation 27% FY26 related work Development 25 2.5x Phase III, 30
Slide 23: Diversified Customer Mix – Traction with Large Pharma & New Clients
Diversified Customer Mix – Traction with Large Pharma & New Clients Customer Mix Customer Revenue Concentration #1 Generics 65% of revenue from 6% #2 27% Big Pharma and 5% Over 500 customers Emerging Biopharma across segments #3 Others 4% 63% #4 Big Pharma 4% 32% Others 8% Top 5-10 17% Emerging Biop
Slide 24: Focus on Differentiated Offerings with Limited Competition
Focus on Differentiated Offerings with Limited Competition Differentiated Offerings Revenue (US$ Mn) from Differentiated Offerings Peptide Potent Sterile Injectables 253 218 175 FY22 FY24 FY26 High Potent On-patent API API (HPAPI) Development and Contribution of Differentiated Offerings to CDMO Reve
Slide 25: 20+ Years Supporting Clients in the ADC Space
20+ Years Supporting Clients in the ADC Space Our Grangemouth facility is the world’s 1st USFDA approved commercial ADC CDMO site and has completed 1,500+ ADC batches Our ADC Credentials ~US$64Mn • HPAPI (from OEL ≥ • Broad bioconjugations FY26 Revenue from ADC services 10ngm3) expertise (ADCs, radi
Slide 26: Maintaining our Best-in-Class Quality Track Record
Maintaining our Best-in-Class Quality Track Record 415 Regulatory Inspections with no OAI Annual Customer Audits Highest ever customer Regulatory Inspections (Ex US FDA) US FDA Inspections audits in a year, up 27% 209 44 197 38 167 163 172 165 2 35 36 36 36 157 140 141 148 29 29 4 4 2 3 26 25 27 116
Slide 27: US Expansion on Track – Seeing Good Customer Interest
US Expansion on Track – Seeing Good Customer Interest Steadily Increasing our Footprint in the US 3 US$200+Mn 450+ HP API, Sterile Injectable, USFDA, EMA, PMDA, HC Manufacturing and API, Formulation Development Sites Investment in US Major Regulatory Accreditation Employees Capabilities US$90Mn inve
Slide 28: FY2030 Vision
FY2030 Vision Become a US$1.2 Billion CDMO Company with ~25% EBITDA Margin by FY2030 Driven By Innovation Integrated Differentiated Customer Margin Cross Related Work Services Offerings Delight Enhancement Selling While maintaining our Best-in-Class Quality track record 27 27
Slide 29: CHG
6 Piramal Pharma Limited
Slide 30: CHG Revenues by Product Segment and Geography
CHG Revenues by Product Segment and Geography Revenue by Product Segment Revenue by Geography Others 21% US Inhalation Intrathecal India 51% 6% Anesthesia Therapy (64%) (15%) Japan 6% Europe 16% Injectable Pain Other Speciality Management (11%) Products (10%) 73% of revenues from regulated markets o
Slide 31: Commercial Presence in Over 100 Countries
Commercial Presence in Over 100 Countries Worldwide Marketing and Distribution Network Established channel relationships and robust commercial infrastructure Direct sales force in the US with strong GPO relationships Direct to market access in key European countries Distribution reach to over 100 co
Slide 32: Inhalation Anesthesia - #1 in the US, Expanding in ex-US Markets
Inhalation Anesthesia - #1 in the US1, Expanding in ex-US Markets Our Strengths Our Market Standing Vertical Integration – Better Control on Cost and Supply Chain Leading Player in Sevoflurane in the US KSM Manufacturing Sevoflurane and Sevoflurane and Dahej, India Desflurane Isoflurane Bethlehem, US Di
Slide 33: Niche and Branded Portfolio with Limited Competition
Niche and Branded Portfolio with Limited Competition Intrathecal Therapy Injectable Pain Management Strengthening Supply Chains to Capture Maintain our Leadership Position1 in the US Market Demand • Established Brands with Leading Market Share – Brand • Established Brands with Leading Market Share S
Slide 34: Building Portfolio of Differentiated and Speciality Products
Building Portfolio of Differentiated and Speciality Products Completed Kenalog® Acquisition – Adds new lever of growth Transaction – Broadens CHG portfolio, adds US$35Mn upfront plus up to revenues with minimal incremental US$65Mn contingent cost, and expands presence in US, considerations. Europe &
Slide 35: Building Portfolio of Differentiated and Speciality Products
Building Portfolio of Differentiated and Speciality Products Focus on Differentiated & Speciality Products Select Examples of Our Experience in Differentiated & Speciality Products E.g. 505(b)(2)’s, Complex Build on our experience with generics, differentiated Gablofen Mitigo differentiated & specia
Slide 36: FY2030 Vision
FY2030 Vision Become a US$600 Million Critical Care Company with 25%+ EBITDA Margin by FY2030 Driven By Leadership in Defend & Expand Market Investment in Productivity and Inhalation Share in Intrathecal & Differentiated and Cost Optimization Anesthesia Injectable Pain Speciality Portfolio 35 35
Slide 37: PCH
6 Piramal Pharma Limited
Slide 38: Fast Growing Consumer Healthcare Company
Fast Growing Consumer Healthcare Company Self-Funded Business with Annual Revenues of over ₹1,200 Crore Building Scale: 15%+ CAGR 1,274 Revenue Growth (In ₹ Crore) 345 25+ brands 2.5x Sales Asset Light Resilient 209 From 3 brands and about Sales have reached Self-funded Absorbed impact of ₹ 100 Cr s
Slide 39: Diversified Portfolio in Large and Attractive Healthcare Segments
Diversified Portfolio in Large and Attractive Healthcare Segments Women’s Health Kids Wellness Skin Care i-pill i-activ Lacto Calamine Contraceptive Menstrual cups Lotions, Facewash, Pill and sanitary pads Sunscreen Wipes, Masks, Bodywash, Eye Care Littles Tetmosol Wipes, Toys, Neko Medicated Soap,
Slide 40: Continuous Investments in Media and Trade Promotion
Continuous Investments in Media and Trade Promotion… Presence Across Platforms Integrated Media Approach: Optimizing digital spends over conventional media Effie Award for Integrated Campaign Excellence: MarTech+ Awards 25 – WinnerUse of Social Media Influencers MarTech for Location-Based Marketing:
Slide 41: Driving Growth in Power Brands
…Driving Growth in Power Brands Strong Growth in our Power Brands Increasing Contribution of Power Brands (In ₹ Cr) 22% CAGR 664 49% 52% 538 42% 45% 370 448 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 40 40
Slide 42: Multi-channel Distribution Network & Tech-enabled Sales Coverage
Multi-channel Distribution Network & Tech-enabled Sales Coverage Presence Across Traditional and Alternate Trade Channels Wide coverage across Strengthening presence Expanding presence on general trade and in modern trade E-Commerce chemist Presence in ~180K chemists Presence in over 13,000 Presence
Slide 43: FY2030 Vision
FY2030 Vision Become a US$200 Million Consumer Healthcare Company with Double-digits EBITDA Margin by FY2030 Driven By 01 Scaling-up Power Omni-Channel Profitable Tech Enablement & Brands Expansion E-commerce Analytics 42 42
Slide 44: JV with AbbVie
6 Piramal Pharma Limited
Slide 45: AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL
AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL One of the market leaders in Indian ophthalmology segment CDMO business supplies ophthalmology products to the JV Ownership Ownership 49% 51% In FY2026, the JV reported revenue of ₹ 526 Cr with PAT margin of 23% Brand Lumigan Combigan Ref
Slide 46: For Investor Queries
For Investor Queries: Gagan Borana Investor Relations and Enterprise Risk Management Email: gagan.borana@piramal.com Our Websites:- Madhusudan Dalmia Piramal Pharma Limited Investor Relations www.piramalpharma.com Email: madhusudan.dalmia@piramal.com CDMO www.piramalpharmasolutions.com Complex Hospi